Nurix Therapeutics, Inc. Financials
This page shows Nurix Therapeutics, Inc. (NRIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Nurix Therapeutics, Inc. has an operating margin of -340.2%, meaning the company retains $-340 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -390.5% the prior year.
Nurix Therapeutics, Inc.'s revenue surged 54.0% year-over-year to $84.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Nurix Therapeutics, Inc. carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.02, Nurix Therapeutics, Inc. holds $7.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Nurix Therapeutics, Inc. generated -$249.5M in operating cash flow, capex of $14.0M consumed most of it, leaving -$263.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Nurix Therapeutics, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Nurix Therapeutics, Inc. generates $0.94 in operating cash flow (-$249.5M OCF vs -$264.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Nurix Therapeutics, Inc. generated $84.0M in revenue in fiscal year 2025. This represents an increase of 54.0% from the prior year.
Nurix Therapeutics, Inc.'s EBITDA was -$276.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.9% from the prior year.
Nurix Therapeutics, Inc. generated -$263.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 44.9% from the prior year.
Nurix Therapeutics, Inc. reported -$264.5M in net income in fiscal year 2025. This represents a decrease of 36.6% from the prior year.
Nurix Therapeutics, Inc. earned $-3.05 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 5.9% from the prior year.
Nurix Therapeutics, Inc. held $247.0M in cash against $0 in long-term debt as of fiscal year 2025.
Nurix Therapeutics, Inc. paid $0.00 per share in dividends in fiscal year 2025.
Nurix Therapeutics, Inc. had 103M shares outstanding in fiscal year 2025. This represents an increase of 35.5% from the prior year.
Nurix Therapeutics, Inc.'s operating margin was -340.2% in fiscal year 2025, reflecting core business profitability. This is up 50.4 percentage points from the prior year.
Nurix Therapeutics, Inc.'s net profit margin was -314.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 40.0 percentage points from the prior year.
Nurix Therapeutics, Inc. invested $316.9M in research and development in fiscal year 2025. This represents an increase of 43.0% from the prior year.
Nurix Therapeutics, Inc. invested $14.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 51.0% from the prior year.
NRIX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.6M+72.0% | $7.9M-82.1% | $44.1M+138.7% | $18.5M+38.9% | $13.3M+5.5% | $12.6M+4.1% | $12.1M-27.1% | $16.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $83.0M-3.6% | $86.1M+10.3% | $78.1M+12.1% | $69.7M+3.6% | $67.2M+21.2% | $55.5M+13.4% | $48.9M-2.2% | $50.0M |
| SG&A Expenses | $13.6M+3.7% | $13.2M-7.9% | $14.3M+22.6% | $11.7M+8.7% | $10.7M-8.5% | $11.7M+0.1% | $11.7M-0.8% | $11.8M |
| Operating Income | -$83.1M+9.1% | -$91.4M-89.1% | -$48.3M+23.1% | -$62.9M+2.8% | -$64.7M-18.4% | -$54.6M-12.5% | -$48.5M-7.3% | -$45.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0-100.0% | $760K | $0-100.0% | $8K-90.2% | $82K-8.9% | $90K0.0% | $90K |
| Net Income | -$78.2M+9.5% | -$86.4M-98.8% | -$43.5M+22.9% | -$56.4M+3.8% | -$58.5M-19.6% | -$49.0M-9.9% | -$44.5M-7.3% | -$41.5M |
| EPS (Diluted) | $-0.83+19.4% | $-1.03-98.1% | $-0.52+22.4% | $-0.67+9.5% | $-0.74-10.4% | $-0.67+5.6% | $-0.71+6.6% | $-0.76 |
NRIX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $688.1M+31.7% | $522.5M-11.7% | $591.6M-3.8% | $615.0M-8.1% | $669.3M+30.3% | $513.6M+0.5% | $511.0M+63.4% | $312.7M |
| Current Assets | $606.8M+37.7% | $440.6M-14.5% | $515.3M-8.6% | $563.7M-9.0% | $619.4M+35.8% | $456.0M+1.3% | $450.2M+79.4% | $251.0M |
| Cash & Equivalents | $247.0M+214.8% | $78.4M-6.9% | $84.3M+11.0% | $75.9M-31.0% | $110.0M+11.1% | $99.0M-15.2% | $116.8M+134.5% | $49.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | $19.0M | N/A | $0 | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $149.4M-0.6% | $150.2M+4.4% | $144.0M+7.3% | $134.1M-5.8% | $142.3M+4.1% | $136.7M-2.6% | $140.3M-2.5% | $143.9M |
| Current Liabilities | $86.5M+5.0% | $82.3M+8.9% | $75.6M-16.0% | $90.0M-6.1% | $95.9M+11.1% | $86.3M+6.8% | $80.8M-7.8% | $87.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $538.7M+44.7% | $372.3M-16.8% | $447.6M-6.9% | $480.9M-8.7% | $527.0M+39.8% | $376.9M+1.7% | $370.7M+119.7% | $168.7M |
| Retained Earnings | -$1.0B-8.5% | -$925.0M-10.3% | -$838.6M-5.5% | -$795.1M-7.6% | -$738.8M-8.6% | -$680.2M-7.8% | -$631.3M-7.6% | -$586.7M |
NRIX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$67.8M-18.2% | -$57.4M+9.1% | -$63.2M-3.4% | -$61.1M-25.3% | -$48.8M-15.6% | -$42.2M-6.2% | -$39.7M+5.4% | -$42.0M |
| Capital Expenditures | $5.1M+89.3% | $2.7M+1.3% | $2.7M-23.2% | $3.5M+65.6% | $2.1M-10.3% | $2.3M+21.2% | $1.9M-32.8% | $2.9M |
| Free Cash Flow | -$73.0M-21.4% | -$60.1M+8.7% | -$65.8M-2.0% | -$64.6M-27.0% | -$50.9M-14.2% | -$44.5M-6.9% | -$41.6M+7.1% | -$44.8M |
| Investing Cash Flow | $346K-99.3% | $50.5M-29.4% | $71.5M+180.0% | $25.5M+118.1% | -$140.8M-559.9% | -$21.3M+83.7% | -$131.1M-469.1% | $35.5M |
| Financing Cash Flow | $236.0M+20333.6% | $1.2M+19150.0% | $6K-99.6% | $1.5M-99.3% | $200.5M+338.1% | $45.8M-80.7% | $237.8M+14539.9% | $1.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NRIX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -612.0%+545.6pp | -1157.6%-1048.0pp | -109.7%+231.0pp | -340.7%+146.1pp | -486.7%-52.9pp | -433.8%-32.4pp | -401.4%-128.8pp | -272.7% |
| Net Margin | -576.1%+518.6pp | -1094.8%-996.1pp | -98.7%+206.7pp | -305.4%+135.4pp | -440.8%-51.8pp | -388.9%-20.5pp | -368.4%-118.1pp | -250.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -11.4%+5.2pp | -16.5%-9.2pp | -7.3%+1.8pp | -9.2%-0.4pp | -8.8%+0.8pp | -9.5%-0.8pp | -8.7%+4.6pp | -13.3% |
| Current Ratio | 7.02+1.7 | 5.35-1.5 | 6.82+0.6 | 6.26-0.2 | 6.46+1.2 | 5.28-0.3 | 5.57+2.7 | 2.86 |
| Debt-to-Equity | 0.28-0.1 | 0.40+0.1 | 0.32+0.0 | 0.280.0 | 0.27-0.1 | 0.36-0.0 | 0.38-0.5 | 0.85 |
| FCF Margin | -537.4%+223.9pp | -761.3%-611.9pp | -149.4%+200.5pp | -349.9%+32.9pp | -382.8%-29.1pp | -353.7%-9.3pp | -344.4%-74.0pp | -270.3% |
Similar Companies
Frequently Asked Questions
What is Nurix Therapeutics, Inc.'s annual revenue?
Nurix Therapeutics, Inc. (NRIX) reported $84.0M in total revenue for fiscal year 2025. This represents a 54.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nurix Therapeutics, Inc.'s revenue growing?
Nurix Therapeutics, Inc. (NRIX) revenue grew by 54% year-over-year, from $54.5M to $84.0M in fiscal year 2025.
Is Nurix Therapeutics, Inc. profitable?
No, Nurix Therapeutics, Inc. (NRIX) reported a net income of -$264.5M in fiscal year 2025, with a net profit margin of -314.9%.
What is Nurix Therapeutics, Inc.'s earnings per share (EPS)?
Nurix Therapeutics, Inc. (NRIX) reported diluted earnings per share of $-3.05 for fiscal year 2025. This represents a -5.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Nurix Therapeutics, Inc.'s EBITDA?
Nurix Therapeutics, Inc. (NRIX) had EBITDA of -$276.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nurix Therapeutics, Inc.'s operating margin?
Nurix Therapeutics, Inc. (NRIX) had an operating margin of -340.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nurix Therapeutics, Inc.'s net profit margin?
Nurix Therapeutics, Inc. (NRIX) had a net profit margin of -314.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nurix Therapeutics, Inc.'s free cash flow?
Nurix Therapeutics, Inc. (NRIX) generated -$263.5M in free cash flow during fiscal year 2025. This represents a -44.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nurix Therapeutics, Inc.'s operating cash flow?
Nurix Therapeutics, Inc. (NRIX) generated -$249.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nurix Therapeutics, Inc.'s total assets?
Nurix Therapeutics, Inc. (NRIX) had $688.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nurix Therapeutics, Inc.'s capital expenditures?
Nurix Therapeutics, Inc. (NRIX) invested $14.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nurix Therapeutics, Inc. spend on research and development?
Nurix Therapeutics, Inc. (NRIX) invested $316.9M in research and development during fiscal year 2025.
How many shares does Nurix Therapeutics, Inc. have outstanding?
Nurix Therapeutics, Inc. (NRIX) had 103M shares outstanding as of fiscal year 2025.
What is Nurix Therapeutics, Inc.'s current ratio?
Nurix Therapeutics, Inc. (NRIX) had a current ratio of 7.02 as of fiscal year 2025, which is generally considered healthy.
What is Nurix Therapeutics, Inc.'s debt-to-equity ratio?
Nurix Therapeutics, Inc. (NRIX) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nurix Therapeutics, Inc.'s return on assets (ROA)?
Nurix Therapeutics, Inc. (NRIX) had a return on assets of -38.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nurix Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Nurix Therapeutics, Inc. (NRIX) had $247.0M in cash against an annual operating cash burn of $249.5M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nurix Therapeutics, Inc.'s Piotroski F-Score?
Nurix Therapeutics, Inc. (NRIX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nurix Therapeutics, Inc.'s earnings high quality?
Nurix Therapeutics, Inc. (NRIX) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Nurix Therapeutics, Inc.?
Nurix Therapeutics, Inc. (NRIX) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.